An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The study will consist of two parts. In Part 1 the study will start enrolling 38 patients and
then further 25 patients up to a total of 63 eligible patients. If the study gives good
results it can be expanded to a total of 160 patients. SU011248 will be administered orally
daily for 4 weeks followed by a 2-week rest at a starting dose of 50 mg [milligrams] with
provision for dose reduction based on tolerability. All patients will receive repeated cycles
of SU011248 until disease progression, occurrence of unacceptable toxicity, or other
withdrawal criteria are met. After discontinuation of treatment, patients will be followed up
in order to collect information on further antineoplastic therapy and survival